NATCAPSUQ · Natural Capsules Ltd · Biotechnology & Drugs
NATCAPSUQ · Natural Capsules Ltd · Biotechnology & Drugs
As of 06 Nov close
52-week range
40.7% below 52-week high
52-week range: as of 06 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 53 days old
Revenue (latest Q)
₹49 Cr
Revenue YoY
PAT YoY
+28.7%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
1.1
P/S (TTM)
1
Sector P/E
36.3
Dividend yield
0.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| NATCAPSUQ (this stock) | Not meaningful (earnings negative over the last 12 months) | 1.1 | -8.1% | -7.0% | 0.52 | 0.0% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
falling 2q
FII
Not available from data source
MF
Not available from data source
Insider trades
| Date | Insider | Type | Qty | Value |
|---|---|---|---|---|
| 24 Jun 2026 | M V Narayanan Kutty | BUY | 25,000 | ₹2.5 lakh |
Bulk/block deals
| canonicalSymbol | date | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| NATCAPSUQ | 2026-08-03 | 0 | 0 | STRONG | BULK |
News timeline
No related news.
Concalls & investor presentations
AI-generatedKey takeaway: The investor presentation from Natural Capsules Limited reported on the company's performance for Q1 FY27, highlighting revenues of ₹48.71 crore and an EBITDA of ₹1.12 crore, reflecting a year-on-year increase of 8% and 251%, respectively. Management noted that the quarter was strong operationally, despite challenges from a previous plant shutdown and a new ERP system that temporarily disrupted billing and dispatch. The gelatine capsules segment showed healthy margins, while the HPMC segment faced demand fluctuations in the US market. The API business experienced mixed results due to geopolitical uncertainties, but management reported progress in contract manufacturing and technical advancements. The presentation emphasized a commitment to R&D and regulatory compliance, with plans to scale API production and enhance profitability. Overall, management expressed confidence in sustaining performance through the financial year.
The presentation conveyed both positive operational achievements and challenges in certain segments.
Sourced from an exchange-filed presentation, dated 13 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: During the Q4 and FY26 earnings conference call, management reported consolidated revenue from operations of Rs. 58.45 crores for Q4 FY26, marking a 55% increase quarter-on-quarter and a 30% increase year-on-year. EBITDA for the quarter improved to Rs. 1.33 crores, with margins at 2.28%. However, for the full year FY26, the company faced a net loss of Rs. 24.66 crores, attributed to operational disruptions and costs from its API subsidiary. Management highlighted that the new HPMC line is ready for production, with revenue anticipated to begin in the second half of FY27, pending customer approvals. The company aims to restore profitability and improve operational clarity following the challenges faced in FY26. Management also discussed ongoing efforts to secure funding and improve liquidity, while emphasizing the importance of regulatory approvals for future growth.
Management reported both growth in revenue and significant losses, indicating a complex financial situation.
Sourced from an exchange-filed transcript, dated 03 Jun 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: The investor presentation from Natural Capsules Limited reported on the company's audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. For Q4FY26, the company achieved revenues of ₹58.45 crore, with a significant EBITDA of ₹1.33 crore, reflecting a 157% increase quarter-on-quarter. Management highlighted that the growth was driven by the successful dispatch of deferred goods from the previous quarter due to a plant shutdown. The presentation noted that the new HPMC line for double-zero capsules is ready, with anticipated revenue flow beginning in the second half of the financial year, pending client approval. Additionally, the company commenced commercial sales in the API segment and executed agreements with Fermbox Bio for advanced fermentation technology, aiming to enhance operational efficiency and profitability. Management expressed confidence in stabilizing operations and restoring growth in FY27.
Management emphasized strong operational performance and growth drivers.
Sourced from an exchange-filed presentation, dated 28 May 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: The investor presentation from Natural Capsules Limited, dated February 13, 2026, provided an overview of the company's financial performance for the quarter ending December 31, 2025. The presentation reported a decline in revenues by 18% quarter-on-quarter and 14% year-on-year, with EBITDA margins at -6.16%. Management noted that operations were affected by a temporary shutdown of the Puducherry unit due to regulatory issues, which have since been resolved. The easing of US trade tariffs on HPMC capsules was highlighted as a positive development, enhancing growth visibility in the US market. The company acknowledged challenges in scaling up its fermentation block for API production but indicated ongoing discussions with potential partners to improve asset utilization. Overall, management expressed a commitment to restoring growth and profitability, citing improved operational visibility and a clear strategy moving forward.
The presentation included both positive developments and significant challenges faced by the company.
Sourced from an exchange-filed presentation, dated 13 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedNatural Capsules Limited (NATCAPSUQ) reported revenue of ₹169.21 crore and EBITDA of ₹17.52 crore for FY2024-25, with a profit before tax of ₹2.79 crore. The company operates in pharmaceutical manufacturing, focusing on capsules and APIs, with international clients. The auditor highlighted key audit matters including uncertain tax positions and trade receivables valuation. No defaults or regulatory penalties were noted, and the company has no material disputes or compliance issues. The Board recommended reappointing directors and maintaining governance standards.
- Revenue of ₹169.21 crore and EBITDA of ₹17.52 crore for FY2024-25.
- No defaults, regulatory penalties, or material disputes noted.
- Key audit matters include uncertain tax positions and trade receivables valuation.
Key takeaway: Natural Capsules Limited shows stable financial performance with no major compliance issues, but faces risks related to its gratuity fund's adequacy and liquidity.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
No item of a kind that needs attention was stored for this company.
Related-Party Transaction
2 occurrencesRecent (last 12 months)
The company approved related party transactions with its subsidiary, Natural Biogenex Private Limited, with a value not exceeding ₹50 crores for a period from the conclusion of the Annual General Meeting till the next Annual General Meeting.
Earlier (1-3 years ago)
The company proposes a related party transaction with its subsidiary Natural Biogenex Private Limited, which exceeds the materiality thresholds under SEBI Listing Regulations (1000 crore or 10% of annual consolidated turnover, whichever is lower). Approval from company members is required as the transaction is not in the ordinary course or at arm's length.
Statutory dues in dispute
2 occurrencesRecent (last 12 months)
The company has undisputed statutory dues including GST, provident fund, and income tax that have been regularly deposited. However, there are pending disputes for service tax payable and penalty, and income tax penalty with specified amounts and periods, being contested in the Commissioner of Central Excise and Commissioner of Income Tax.
Earlier (1-3 years ago)
The company has outstanding statutory dues under various acts, including Service Tax and Income Tax, with amounts ranging from ₹10,399 to ₹22,08,948, pending before different commissioners as of various fiscal years.